7BWR image
Entry Detail
PDB ID:
7BWR
EMDB ID:
Keywords:
Title:
Mycobacterium smegmatis arabinosyltransferase complex EmbB2-AcpM2 in substrate DPA bound asymmetric "active state"
Biological Source:
PDB Version:
Deposition Date:
2020-04-15
Release Date:
2020-05-27
Method Details:
Experimental Method:
Resolution:
3.50 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Integral membrane indolylacetylinositol arabinosyltransferase EmbB
Chain IDs:A, B
Chain Length:1082
Number of Molecules:2
Biological Source:Mycolicibacterium smegmatis MC2 155
Polymer Type:polypeptide(L)
Description:Meromycolate extension acyl carrier protein
Chain IDs:C, D
Chain Length:99
Number of Molecules:2
Biological Source:Mycolicibacterium smegmatis MC2 155
Primary Citation
Cryo-EM snapshots of mycobacterial arabinosyltransferase complex EmbB2-AcpM2.
Protein Cell 11 505 517 (2020)
PMID: 32363534 DOI: 10.1007/s13238-020-00726-6

Abstact

Inhibition of Mycobacterium tuberculosis (Mtb) cell wall assembly is an established strategy for anti-TB chemotherapy. Arabinosyltransferase EmbB, which catalyzes the transfer of arabinose from the donor decaprenyl-phosphate-arabinose (DPA) to its arabinosyl acceptor is an essential enzyme for Mtb cell wall synthesis. Analysis of drug resistance mutations suggests that EmbB is the main target of the front-line anti-TB drug, ethambutol. Herein, we report the cryo-EM structures of Mycobacterium smegmatis EmbB in its "resting state" and DPA-bound "active state". EmbB is a fifteen-transmembrane-spanning protein, assembled as a dimer. Each protomer has an associated acyl-carrier-protein (AcpM) on their cytoplasmic surface. Conformational changes upon DPA binding indicate an asymmetric movement within the EmbB dimer during catalysis. Functional studies have identified critical residues in substrate recognition and catalysis, and demonstrated that ethambutol inhibits transferase activity of EmbB by competing with DPA. The structures represent the first step directed towards a rational approach for anti-TB drug discovery.

Legend

Protein

Chemical

Disease

Primary Citation of related structures